Friday, July 30, 2021
The latest medical news


COVID-19 reinfection rate less than 1% for those with severe illness

A review of more than 9,000 U.S. patients with severe COVID-19 infection showed less than 1% contracted the illness again,…

By Staff , in COVID-19 , at June 15, 2021 Tags:


A review of more than 9,000 U.S. patients with severe COVID-19 infection showed less than 1% contracted the illness again, with an average reinfection time of 3.5 months after an initial positive test. Those are the findings from a study conducted by researchers from the University of Missouri School of Medicine and MU Health Care.

The researchers teamed up with the MU Institute for Data Science and Informatics and the Tiger Institute for Health Innovation to review data from 62 U.S. health care facilities. They found 63 of the 9,119 patients (0.7%) with severe COVID-19 infection contracted the virus a second time, with a mean reinfection period of 116 days. Of the 63 who were reinfected, two (3.2%) died. Patients categorized as non-white were at greater risk of reinfection than white patients.

“Our analysis also found asthma and nicotine dependence were associated with reinfection,” said lead researcher Adnan I. Qureshi, MD, a professor of clinical neurology at the MU School of Medicine. “However, there was a significantly lower rate of pneumonia, heart failure and acute kidney injury observed with reinfection compared with primary infection.”

Qureshi defined reinfection by two positive tests separated by an interval greater than 90 days after the initial infection resolved, as confirmed by two or more consecutive negative tests. He analyzed data from patients who received serial tests between December 2019 and November 2020.

“This is one of the largest studies of its kind in the U.S., and the important message here is that COVID-19 reinfection after an initial case is possible, and the duration of immunity that an initial infection provides is not completely clear,” Qureshi said.

In addition to Qureshi, the study authors include fellow MU School of Medicine collaborators Iryna Lobanova, MD, research specialist in the Department of Neurology; S. Hasan Naqvi, MD, associate professor of clinical medicine; William Baskett, graduate student; Wei Huang, graduate student; and Chi-Ren Shyu, PhD, Director, MU Institute for Data Science and professor of Informatics, Electrical Engineering and Computer Science.

Their study, “Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing,” was recently published in the journal Clinical Infectious Diseases. Support for this study was provided by the National Institutes of Health. The authors of the study declare that they have no conflicts of interest related to this study and the content does not necessarily represent the official views of the National Institutes of Health.

This article is based on a press release from the University of Missouri-Columbia.

Staff
The team at The Medical Dispatch

Comments